TURKISH JOURNAL OF MEDICAL SCIENCES · 2021 · 33 citations · 30 references
MedicinePharmaceutical AnalysisPharmacologyBiochemical PharmacologyExperimental PharmacologyGeneral PharmacologyDiabetes MellitusDiabetes PharmacotherapyInsulin ResistanceOral Antidiabetic AgentsAlbendazole TherapyAntidiabetic ActivityAntidiabetic Drug TherapyBenzimidazole FungicidesOral Antidiabetic Medications
Background/aim: The aim of this study is to determine the effects of different concentrations of albendazole and lansoprazole, which were benzimidazole derivatives, on endocrinologic and biochemical parameters in experimental type 2 diabetic (T2D) rats. Materials and methods: In this study, 46 male Wistar Albino rats were used. Animals were divided as healthy control (0.1 mL/rat/day saline, s.c, n = 6), diabetes control (0.1 mL/rat/day saline, s.c, n = 8), diabetes+low-dose albendazole (5 mg/kg, oral, n = 8), diabetes+high- dose albendazole (10 mg/kg, oral n = 8), diabetes+low-dose lansoprazole (15 mg/kg, subcutaneous, n = 8), and diabetes+high-dose lansoprazole (30 mg/kg, subcutaneous, n = 8). All groups were treated for 8 weeks. The blood samples were analyzed by autoanalyzer and ELISA kits for biochemical and endocrinological parameters, respectively. Results: Glucose, HbA1c, triglyceride, low density cholesterol (LDL), leptin, and Homeostatic Model Assessment for insulin resistance (HOMA-IR) levels increased and insulin and HOMA-β levels decreased in the diabetic rats compared to the healthy control group. The glucose, HbA1c, and triglyceride levels were partially decreased; however, insulin and HOMA-β levels were increased by low-dose albendazole therapy. The high dose of lansoprazole treatment increased insulin level. Conclusion: The lansoprazole and albendazole treatments can be a potential drug or combined with antidiabetic drugs in T2D treatment by Adenosine 5′-monophosphate activated protein kinase (AMPK), peroxisome proliferator-activated receptor (PPAR), incretin-like effect and other antidiabetic mechanisms. It may be beneficial to create an effective treatment strategy by developing more specific substances with benzimidazole scaffold.
30
Role of AMP-activated protein kinase in mechanism of metformin action
Gaochao Zhou, Robert P. Myers, Ying Li et al. · Journal of Clinical Investigation · 2001 · 5.4K citations
Structural basis of AMPK regulation by small molecule activators
Bing Xiao, Matthew J. Sanders, David Carmena et al. · Nature Communications · 2013 · 543 citations · Full text